153 related articles for article (PubMed ID: 24805876)
1. Prognostic value of matrix metalloprotease-1/protease-activated receptor-1 axis in patients with prostate cancer.
Wang J; Liu D; Zhou W; Wang M; Xia W; Tang Q
Med Oncol; 2014 Jun; 31(6):968. PubMed ID: 24805876
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of matrix metalloproteinase-1/ proteinase-activated receptor-1 signaling axis in hepatocellular carcinoma.
Liao M; Tong P; Zhao J; Zhang Y; Li Z; Wang J; Feng X; Hu M; Pan Y
Pathol Oncol Res; 2012 Apr; 18(2):397-403. PubMed ID: 21909684
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1) in gastric cancer.
Fujimoto D; Hirono Y; Goi T; Katayama K; Yamaguchi A
Anticancer Res; 2008; 28(2A):847-54. PubMed ID: 18507028
[TBL] [Abstract][Full Text] [Related]
4. Correlation between MMP1-PAR1 axis and clinical outcome of primary gallbladder carcinoma.
Du X; Wang S; Lu J; Cao Y; Song N; Yang T; Dong R; Zang L; Yang Y; Wu T; Li J
Jpn J Clin Oncol; 2011 Sep; 41(9):1086-93. PubMed ID: 21835828
[TBL] [Abstract][Full Text] [Related]
5. MMP-1/PAR-1 signal transduction axis and its prognostic impact in esophageal squamous cell carcinoma.
Peng HH; Zhang X; Cao PG
Braz J Med Biol Res; 2012 Jan; 45(1):86-92. PubMed ID: 22086466
[TBL] [Abstract][Full Text] [Related]
6. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.
Zhong WD; Han ZD; He HC; Bi XC; Dai QS; Zhu G; Ye YK; Liang YX; Qin WJ; Zhang Z; Zeng GH; Chen ZN
Oncology; 2008; 75(3-4):230-6. PubMed ID: 18852494
[TBL] [Abstract][Full Text] [Related]
7. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
8. Expression of SOCSs in human prostate cancer and their association in prognosis.
Zhu JG; Dai QS; Han ZD; He HC; Mo RJ; Chen G; Chen YF; Wu YD; Yang SB; Jiang FN; Chen WH; Sun ZL; Zhong WD
Mol Cell Biochem; 2013 Sep; 381(1-2):51-9. PubMed ID: 23666742
[TBL] [Abstract][Full Text] [Related]
9. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
10. Combined upregulation of matrix metalloproteinase-1 and proteinase-activated receptor-1 predicts unfavorable prognosis in human nasopharyngeal carcinoma.
Yang R; Xu Y; Li P; Zhang X; Wang J; Gu D; Wang Y
Onco Targets Ther; 2013; 6():1139-46. PubMed ID: 23986644
[TBL] [Abstract][Full Text] [Related]
11. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of matrix metalloproteinase-1 and proteinase-activated receptor-1 promotes the progression of human gliomas.
Zhang Y; Zhan H; Xu W; Yuan Z; Lu P; Zhan L; Li Q
Pathol Res Pract; 2011 Jan; 207(1):24-9. PubMed ID: 21087829
[TBL] [Abstract][Full Text] [Related]
13. Decreased expression of myosin light chain MYL9 in stroma predicts malignant progression and poor biochemical recurrence-free survival in prostate cancer.
Huang YQ; Han ZD; Liang YX; Lin ZY; Ling XH; Fu X; Cai C; Bi XC; Dai QS; Chen JH; He HC; Chen YR; Jiang FN; Zhong WD
Med Oncol; 2014 Jan; 31(1):820. PubMed ID: 24338276
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1).
Kim SJ; Shin JY; Lee KD; Bae YK; Choi IJ; Park SH; Chun KH
PLoS One; 2011; 6(9):e25103. PubMed ID: 21966428
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of NDRG2 and NDRG3 in prostate cancer patients undergoing radical prostatectomy.
Ren GF; Tang L; Yang AQ; Jiang WW; Huang YM
Histol Histopathol; 2014 Apr; 29(4):535-42. PubMed ID: 24222185
[TBL] [Abstract][Full Text] [Related]
16. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
Guan Y; Wu Y; Liu Y; Ni J; Nong S
Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
[TBL] [Abstract][Full Text] [Related]
17. Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis.
Zhang X; Wang W; True LD; Vessella RL; Takayama TK
Prostate; 2009 May; 69(7):727-36. PubMed ID: 19170048
[TBL] [Abstract][Full Text] [Related]
18. Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer.
Zhou L; Xia D; Zhu J; Chen Y; Chen G; Mo R; Zeng Y; Dai Q; He H; Liang Y; Jiang F; Zhong W
Clin Transl Oncol; 2014 Oct; 16(10):906-13. PubMed ID: 24659377
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
20. Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.
Huang L; Li M; Wang D; He J; Wu W; Zeng Q; Li J; Xiao M; Hu J; He Y; Li Y; Mai L; Liu W
Hum Pathol; 2016 Jan; 47(1):109-14. PubMed ID: 26546252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
